Heart valve allograft litigation
This article was originally published in The Gray Sheet
Executive Summary
Remanded to the U.S. District Court for the Northern District of Illinois in a July 27 opinion of the Seventh Circuit Court of Appeals. At issue is whether FDA "promulgated a back door amendment" to replacement heart valve regulations, thereby denying the plaintiffs, Northwest Tissue Center and Oregon Tissue Bank, "the right to notice and comment on the regulation of allografts." In 1991, the agency issued a notice of applicability of a final rule (NAFR) stating that heart valve allografts are subject to replacement heart valve regs, including a 1987 call for premarket approval applications for the devices. Previously, according to the tissue banks, FDA indicated that despite its "authority over processors of human source valves," it would not exercise that authority. The appeals court upheld the district court's dismissal of two other issues in the litigation ("The Gray Sheet" Nov. 16, In Brief).
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.